NYSE

Maximus, INC.

MMS

2 stories

$2.9B Market cap · 2026-10-06

Maximus: A Discount To Peers, Even If The Recent Contract Change Is Permanent

Maximus trades at 6.9x fiscal 2026 EPS guidance after the VA paused medical-exam incentives, below Leidos and Booz Allen despite lower…

MMS $2.9B

Avalon Capital Research Sep 24 4 clicks

@finphysnerd Sep 22 4 clicks

Myles on X

@HatfieldCapital @RealHerbHoover From what I've read $MMS has some exposure to va healthcare repricing as well. More importantly the rest of the business is lower quality. No defence/intelligence exposure, some segments overearning (natural disaster work and soft services volumes). Still looks cheap.

Investor Letters

Letters that discuss MMS.

Royce Investment Partners Royce Capital Fund–Small-Cap Portfolio Manager Commentary Year-to-Date Through 6/30/26 AMKR $13BFLEX $42BMMS $2.9B
Royce Investment Partners Royce Small-Cap Fund Manager Commentary year-to-date period ended 6/30/26 ACA $7.2BADMA $2.3BESI $9B